Biotech News
Related news
SUPNSupernus2026-05-27 20:30 EST
Supernus Pharmaceuticals to Participate in June Investor Conferences
ECORelectroCore2026-06-17 12:00 EST
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
KTTAPasithea Therapeutics2026-07-21 11:00 EST
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTAPasithea Therapeutics2026-06-15 11:02 EST
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
PRAXPraxis Precision Medicines2026-06-04 20:01 EST
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
ALKSAlkermes plc2026-06-03 20:05 EST
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
ABOSAcumen Pharmaceuticals2026-07-15 11:30 EST
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
HRMYHarmony Biosciences2026-05-27 12:05 EST
Harmony Biosciences to Participate in Upcoming Investor Conferences
Supernus
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...
Recent company news
SUPNSupernus2026-08-03 10:35 EST
Supernus Announces Second Quarter 2026 Financial Results
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
SUPNSupernus2026-07-14 12:30 EST
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
SUPNSupernus2026-05-27 20:30 EST
Supernus Pharmaceuticals to Participate in June Investor Conferences
Stock data
- Close
- 45.85 USD
- Market cap
- 2.56B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States